The efficicancy of Cystatine C as the biomarker for acute kidney injury

  • Abe Takaya
    Center of Blood Purification Medicine, Iwate Medical University Hospital
  • Murai Mihoko
    Center of Blood Purification Medicine, Iwate Medical University Hospital
  • Sato Toshiya
    Center of Blood Purification Medicine, Iwate Medical University Hospital
  • Chiba Kenta
    Center of Blood Purification Medicine, Iwate Medical University Hospital
  • Obara Wataru
    Center of Blood Purification Medicine, Iwate Medical University Hospital

Bibliographic Information

Other Title
  • 急性腎障害に対するバイオマーカーとしてのシスタチンCの有用性
  • キュウセイジンショウガイ ニ タイスル バイオマーカー ト シテ ノ シスタチン C ノ ユウヨウセイ

Search this article

Abstract

<p>Acute kidney injury (AKI) is diagnosed by rising serum creatinine (Cr) level (increase rate) and decreasing urine volume. However, as the serum Cr level has a low sensitivity for glomerular filtration rate loss in early stages, biomarkers that diagnose AKI more specifically and earlier, as well as reflect the severity are expected. As a low molecular weight protein (molecular weight is 13.3kDa) which is produced in a constant amount from whole nucleated cells, Cystatin C (Cys-C) is expected to be a biomarker of AKI, since it begins to rise above the reduced renal function in early stages compared with Cr. The most usefulness of Cys-C is being compatible with automatic biochemical analyzer, and possibility to practically apply in clinic. AKI is affected by complex factors such as damaged parts of the kidney or time elapsed since the damage occurred. Thus, not only Cys-C but various combinations of biomarkers are required, and the establishment of new biomarkers is urgently needed.</p>

Journal

Details 詳細情報について

Report a problem

Back to top